RxDoctor Payments Data

Rodolfo Rios, MD

Ophthalmology · Lewes, DENPI 1609889658

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 10 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 7 manufacturers reported payments, led by AbbVie at 26.7% of the total. Reporting peaked in 2019 at $66 and has fallen 65.7% since, to $23 in 2025. That places this record below the midpoint for ophthalmology clinicians in DE, where the typical reported total is $1,099.

$230in general payments, 2019–2025

Across 10 payments — averaging $23.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$62
  • Rxsight Inc$50
  • Aerie Pharmaceuticals, Inc.$37
  • Coopervision Inc.$23
  • Amgen$22
  • Novartis$21
  • plus $16 from 1 others

What the payments were for

  • Food & beverage$230100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$230 in reported general payments places this provider in the 15th percentile of 49 ophthalmology providers in Delaware.

See all ophthalmology providers in Delaware

Medicare billing

Part B allowed, 2024
$227,088
Medicare patients
729
Services billed
2,762

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine22$37,517
LumiganBimatoprost65$25,815
Travoprost139$15,818
VyzultaLatanoprostene Bunod41$14,953
RocklatanNetarsudil Mesylat/Latanoprost27$11,936
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol42$8,604
Bimatoprost93$7,260
SimbrinzaBrinzolamide/Brimonidine Tart12$5,891
Latanoprost361$4,909
Prednisolone Acetate145$4,197
Timolol Maleate278$4,145
Fluorometholone53$3,289
Bromfenac Sodium30$2,593
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha205$2,087
Ketorolac Tromethamine66$1,437

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan$62$63,33187 claims
Aerie Pharmaceuticals, Inc.Rocklatan$37$11,93627 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 15th percentile of 49 ophthalmology providers in Delaware.

Other ophthalmology in Lewes

See the full list for Delaware

Where these figures come from

Is this you, or does something look wrong? →